Premium
Role of pharmacist in cardiovascular disease‐related health promotion and in hypertension and dyslipidemia management: a cross‐sectional study in the S tate of Q atar
Author(s) -
El Hajj Maguy Saffouh,
Mahfoud Ziyad R.,
Al Suwaidi Jassim,
Alkhiyami Dania,
Alasmar Aya Riyad
Publication year - 2016
Publication title -
journal of evaluation in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.737
H-Index - 73
eISSN - 1365-2753
pISSN - 1356-1294
DOI - 10.1111/jep.12477
Subject(s) - medicine , cross sectional study , pharmacist , health promotion , family medicine , psychological intervention , dyslipidemia , promotion (chess) , disease , public health , pharmacy , environmental health , nursing , pathology , politics , political science , law
Rationale, aims and objectives In Q atar, cardiovascular diseases ( CVD ) have recently become the leading cause of morbidity and mortality. Prevention, detection and management of CVD risk factors reduce CVD chance. The study objectives were to assess Q atar pharmacists' involvement in CVD health promotion, to identify the activities that they currently provide to patients with CVD risk factors, to describe their attitudes towards their involvement in CVD prevention and to assess their perceived barriers for provision of CVD prevention services Method We conducted a cross‐sectional survey of community and ambulatory pharmacists in Q atar. Pharmacist characteristics, involvement in CVD ‐related activities along with their attitudes and perceived barriers were analysed using frequency distributions. Bivariate linear regression models were used to test for associations between CVD health promotion activity score and each variable. Variables with a P ‐value of 0.20 or less were included in the multivariate model. Results A total of 141 pharmacists completed the survey (response rate 60%). More than 70% responded with rarely or never to 6 out of the 10 CVD health promotion activities. Eighty‐four per cent and 68% always or often describe to patients the appropriate time to take antihypertensive medications and the common medication adverse effects, respectively. Yet, 50% rarely or never review the medication refill history or provide adherence interventions. Lack of CVD educational materials was the top perceived barrier (55%) in addition to lack of having private counselling area (44.6%), and lack of time (38.3%). Females and community pharmacists were more involved in CVD health promotion ( P = 0.046 and P = 0.017, respectively) than their counterparts. Health promotion practice increased with increasing attitudes score and decreased with increased barriers score ( P = 0.012 and P = 0.001). Conclusion The scope of pharmacy practice in CVD prevention is limited in Q atar. Efforts need to be exerted to increase pharmacists' involvement in CVD prevention